- Conditions
- Metastatic Castration Resistant Prostate Cancer
- Interventions
- VERU-111
- Drug
- Lead sponsor
- Veru Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 13
- States / cities
- Golden, Colorado • Miami, Florida • Jeffersonville, Indiana + 10 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 601–624
of 2,480
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Pancreatic Cancer Metastatic, Pancreatic Cancer Stage IV, Stage IV Pancreatic Cancer
- Interventions
- SBP-101, nab-paclitaxel, Gemcitabine Injection
- Drug
- Lead sponsor
- Panbela Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 3
- States / cities
- La Jolla, California • Gainesville, Florida • Rochester, New York
- Conditions
- Advanced Solid Tumor, Advanced Breast Cancer, Advanced Gastric Cancer
- Interventions
- IMM2902
- Drug
- Lead sponsor
- ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 135 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts • Dallas, Texas • Fairfax, Virginia
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Cytarabine, Daunorubicin, Daunorubicin Hydrochloride, Pinometostat
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 14 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 3
- States / cities
- New Haven, Connecticut • Baltimore, Maryland • Columbus, Ohio
- Conditions
- Multiple Myeloma
- Interventions
- zevor-cel
- Biological
- Lead sponsor
- CARsgen Therapeutics Co., Ltd.
- Industry
- Eligibility
- 18 Years to 79 Years
- Enrollment
- 105 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2034
- U.S. locations
- 12
- States / cities
- Phoenix, Arizona • San Francisco, California • Denver, Colorado + 8 more
- Conditions
- Severe Hemophilia A
- Interventions
- MARSTACIMAB
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 12 Years to 74 Years · Male only
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 6
- States / cities
- La Jolla, California • Los Angeles, California • San Diego, California + 1 more
- Conditions
- Optical Coherence Tomography of Retina, Alzheimer Disease
- Interventions
- retinal imaging with low-cost OCT-a/LCI device
- Device
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 82 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Non-small Cell Lung Cancer (NSCLC), Anaplastic Lymphoma Kinase (ALK) Positive
- Interventions
- gilteritinib
- Drug
- Lead sponsor
- Astellas Pharma Global Development, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 10
- States / cities
- Fullerton, California • Orange, California • Edwards, Colorado + 7 more
- Conditions
- Ulcerative Colitis
- Interventions
- UTTR1147A, UTTR1147A Placebo, Vedolizumab, Vedolizumab Placebo
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 195 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 2
- States / cities
- Greenville, North Carolina • Salt Lake City, Utah
- Conditions
- B-cell Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia
- Interventions
- Cyclophosphamide injection, Fludarabine Injection, CD19-CD34t metabolically programmed CAR transduced T-cells
- Drug · Biological
- Lead sponsor
- Medical University of South Carolina
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Charleston, South Carolina
- Conditions
- Pancreatic Cancer
- Interventions
- ganitumab, capecitabine, gemcitabine hydrochloride, 3-dimensional conformal radiation therapy
- Biological · Drug · Radiation
- Lead sponsor
- Radiation Therapy Oncology Group
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 10
- States / cities
- Orange, California • Newark, Delaware • Louisville, Kentucky + 6 more
- Conditions
- Metastatic Prostate Cancer, Metastatic Castration-resistant Prostate Cancer
- Interventions
- Tazemetostat, Abiraterone/prednisone, Enzalutamide
- Drug
- Lead sponsor
- Epizyme, Inc.
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 102 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 16
- States / cities
- San Diego, California • Denver, Colorado • Port Saint Lucie, Florida + 12 more
- Conditions
- Adrenomyeloneuropathy Form (AMN) of X-linked Adrenoleukodystrophy (X-ALD)
- Interventions
- VK0214, Placebo
- Drug · Other
- Lead sponsor
- Viking Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 4
- States / cities
- Palo Alto, California • Gainesville, Florida • Baltimore, Maryland + 1 more
- Conditions
- Advanced Cancer, Advanced Malignancies, Bladder Cancer, Cervical Cancer, Esophageal Cancer, Gastric Cancer, Gastroesophageal-junction Cancer (GEJ), Head and Neck Squamous Cell Carcinoma (HNSCC), Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Renal Cell Carcinoma (RCC), Triple Negative Breast Cancer (TNBC)
- Interventions
- AB598, Zimberelimab, Fluorouracil, Leucovorin, Oxaliplatin
- Drug
- Lead sponsor
- Arcus Biosciences, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 11
- States / cities
- Phoenix, Arizona • Jacksonville, Florida • Lake City, Florida + 8 more
- Conditions
- Recurrent Glioblastoma Multiforme (GBM), Grade 3 Isocitrate Dehydrogenase (IDH) Wildtype Astrocytoma, Grade 3 or 4 Astrocytoma, Glioblastoma Surgery
- Interventions
- Icapamespib
- Drug
- Lead sponsor
- Samus Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 5
- States / cities
- Los Angeles, California • San Diego, California • New York, New York + 2 more
- Conditions
- Alzheimer's Disease
- Interventions
- AGN-242071, Placebo, Donepezil, Memantine
- Drug
- Lead sponsor
- Allergan
- Industry
- Eligibility
- 55 Years to 85 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018
- U.S. locations
- 6
- States / cities
- Costa Mesa, California • Irvine, California • Lemon Grove, California + 2 more
- Conditions
- Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
- Interventions
- Cobimetinib, Enasidenib Mesylate
- Drug
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Solid Tumor, Colorectal Cancer, Non Small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck, Urothelial Carcinoma, Endometrial Cancer, Gastroesophageal Junction Adenocarcinoma, Gastric Adenocarcinoma, Solid Tumors With PIK3Ca Mutation
- Interventions
- TPST-1495 twice daily, TPST-1495 once daily or on intermittent schedule, Pembrolizumab
- Drug
- Lead sponsor
- Tempest Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 89 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 11
- States / cities
- Aurora, Colorado • Baltimore, Maryland • Springfield, Massachusetts + 8 more
- Conditions
- Breast Cancer, Colorectal Cancer, Uveal Melanoma, Cutaneous Melanoma, Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma
- Interventions
- TBio-4101, Pembrolizumab
- Biological · Drug
- Lead sponsor
- Turnstone Biologics, Corp.
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 11
- States / cities
- Irvine, California • Hollywood, Florida • Miami, Florida + 8 more
- Conditions
- Leukemia, Lymphocytic
- Interventions
- enzastaurin
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 4
- States / cities
- Duarte, California • Chicago, Illinois • New York, New York + 1 more
- Conditions
- Recurrent Plasmablastic Lymphoma, Refractory Plasmablastic Lymphoma
- Interventions
- Biospecimen Collection, Computed Tomography, Positron Emission Tomography, Teclistamab
- Procedure · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2027
- U.S. locations
- 14
- States / cities
- Duarte, California • Irvine, California • Los Angeles, California + 10 more
- Conditions
- Metastatic Cancer, Solid Tumor
- Interventions
- Sym021, Sym022, Sym023, Irinotecan Hydrochloride
- Drug
- Lead sponsor
- Symphogen A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 78 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 12
- States / cities
- Aurora, Colorado • Jacksonville, Florida • Tampa, Florida + 9 more
- Conditions
- EGFR Mutated EGFR TKI Naive Metastatic NSCLC
- Interventions
- Momelotinib (MMB), Erlotinib
- Drug
- Lead sponsor
- Sierra Oncology LLC - a GSK company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 3
- States / cities
- Duarte, California • Palo Alto, California • Whittier, California
- Conditions
- Recurrent Endometrial Carcinoma, Recurrent Endometrial Clear Cell Adenocarcinoma, Recurrent Endometrial Endometrioid Adenocarcinoma, Recurrent Endometrial Low Grade Endometrioid Adenocarcinoma, Recurrent Ovarian Clear Cell Adenocarcinoma, Recurrent Ovarian Endometrioid Adenocarcinoma, Recurrent Ovarian High Grade Serous Adenocarcinoma, Recurrent Ovarian Low Grade Endometrioid Adenocarcinoma, Recurrent Platinum-Resistant Ovarian Carcinoma
- Interventions
- BET Bromodomain Inhibitor ZEN-3694, Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Tuvusertib, X-Ray Imaging
- Drug · Procedure
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 65 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 14
- States / cities
- Augusta, Georgia • Chicago, Illinois • Iowa City, Iowa + 8 more